Federal Register of Legislation - Australian Government

Primary content

PB 119 of 2010 Specifications as made
This Specification amends the National Health Act (Pharmaceutical Benefits - Early Supply) - specification under subsection 84AAA(2) Instrument 2009 (No. PB 30 of 2009) to list the medicines for which Pharmaceutical Benefits Scheme Safety Net entitlements will not apply when the next supply of the same medicine is obtained within 20 days.
Administered by: Health
Registered 30 Nov 2010
Tabling HistoryDate
Tabled HR08-Feb-2011
Tabled Senate08-Feb-2011
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014



Instrument number PB 119 of 2010

National Health Act (Pharmaceutical Benefits – Early Supply) Amendment December 2010 - Specification Under Subsection 84AAA(2)


Amendment determination under subsection 84AAA(2) of the National Health Act 1953


I, Adriana Platona, Assistant Secretary, Pharmaceutical Evaluation Branch, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.


Dated          29 November 2010




Assistant Secretary

Pharmaceutical Evaluation Branch

Department of Health and Ageing




Amendment determination — Pharmaceutical Benefits - Early Supply



1          Name of Instrument


(1)           This Instrument is the National Health Act (Pharmaceutical Benefits – Early Supply) Amendment December 2010 - specification under subsection 84AAA(2).


(2)           This Instrument may also be cited as “No. PB 119 of 2010”.


2          Commencement


This Instrument commences on 1 December 2010.



3          Amendment of PB 30 of 2009


Schedule 1 amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009, PB 30 of 2009.


Schedule 1        Amendments

[1]                                  Schedule 1, after item dealing with Clopidogrel with aspirin

insert in the columns in the order indicated:



Powder for injection 80 mg (as acetate) with solvent, syringe and needles






[2]                                  Schedule 1, item dealing with Anakinra

Omit from the columns in the order indicated:



Injection 100 mg in 0.67 mL single use pre-filled syringe